Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ajay Pandita

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Cancer Discovery|May 16, 2012
PPM1H is a p27 phosphatase implicated in trastuzumab resistanceSi Tuen Lee-Hoeflich, Thinh Q Pham, Don Dowbenko, et al.
Nature|May 28, 2010
The mutation spectrum revealed by paired genome sequences from a lung cancer patientWilliam Lee, Zhaoshi Jiang, Jinfeng Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2014
Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefitHartmut Koeppen, Wei Yu, Jiping Zha, et al.
Science Translational Medicine|March 18, 2011
CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphomaBart Burington, Peng Yue, Xiaoyan Shi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of originAlbert Lai, Samir Kharbanda, Whitney B Pope, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Cancer Discovery|May 16, 2012
PPM1H is a p27 phosphatase implicated in trastuzumab resistanceSi Tuen Lee-Hoeflich, Thinh Q Pham, Don Dowbenko, et al.
Nature|May 28, 2010
The mutation spectrum revealed by paired genome sequences from a lung cancer patientWilliam Lee, Zhaoshi Jiang, Jinfeng Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2014
Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefitHartmut Koeppen, Wei Yu, Jiping Zha, et al.
Science Translational Medicine|March 18, 2011
CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphomaBart Burington, Peng Yue, Xiaoyan Shi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of originAlbert Lai, Samir Kharbanda, Whitney B Pope, et al.
Pageof 3